Business
Compound Discovery
Compound Discovery.
About this update from Immupharma Plc
[{"type":"text","content":"\n Immupharma PLC\n22 August 2007\n\n\n\n\nFor Immediate Release 22 August 2007\n\n\n ImmuPharma PLC\n\n ImmuPharma discovers new lead drug candidate for inflammation\n\n\nImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug\ndiscovery and development company, announced today that following its discovery\nactivities on its chemical library, it has discovered a new molecular series\nwith potential application in inflammatory/allergic conditions such as asthma\nand rheumatoid arthritis. These molecules, in the programme code-named\nIPP-201007, have utility as selective phospholipase A2 subtype inhibitors and\nare already patented through ImmuPharma's library broad patent.\n\nImmuPharma's long-term pipeline includes a proprietary library or over 300,000\nsmall molecules with a 70% drug likeness. These large number of molecules are\nall patent-protected, with the patent already having been issued in a number of\ncountries including the United States. The present discovery is also paving the\nway for newly patented additional chemical libraries expanding thereby the scope\nof our primary proprietary library.\n\n\nDr Robert Zimmer, MD, PhD, ImmuPharma's Chief Scientific Officer commented:\n\n'The discovery of these exciting molecules and their derivatives validates our\nlong-term pipeline prospects and are just the first of other potential lead\ndrugs to be discovered from our libraries of molecules. IPP-201007 further\naugments our pipeline of lead drugs in building a pharma company'.\n\n\n\n\nFor further information please contact:\n\nImmuPharma PLC:\n\nDimitri Dimitriou, Chief Executive Officer +44 20 7152 4080\nDr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 7650\nRichard Warr, Chairman +44 20 7152 4080\n\nBuchanan Communications + 44 20 7466 5000\nLisa Baderoon\nRebecca Skye Dietrich\n\nLandsbanki Securities (UK) Limited\nThilo Hoffmann +44 20 7426 7710\n \n\nFor company information, visit www.immupharma.com\n\n\n\nNotes to Editors:\n\nAbout ImmuPharma\n\nImmuPharma PLC is a drug discovery and development company headquartered in\nLondon, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has\nresearch operations in France (ImmuPharma (France) SA) and Switzerland\n(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs,\nlargely based on peptide ther...